Michael J. Fox Foundation for Parkinson's Research — Biomedical Watch V2

Traitements8programmes

Essais4liés

Publications3liées

SourceDBlocale

Traitements

8

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
[18F] AV-133 PET ImagingThis study is a single-center, longitudinal study and will be conducted at the Institute for Neurodegenerative (INDD) Site in New Haven, CT. This study aims to recruit participants from the ongoing Parkinson's Progression Markers Initiative AV-133 Prodromal Imaging sub study \[PPMI 015\] to obtain a second comparison imaging scan. In addition to being imaged with the standard Positron Emission Tomography (PET) camera after the \[18F\]AV133 injection in the PPMI 015 sub study, participants agreeing to a second scan will be imaged with the NeuroEXPLORER (NX) PET camera per this protocol. This study will enroll approximately 25 participants at the INDD site. The dual PET scans will be completed at baseline, 1-and 2- years follow up. Participants may be asked to undergo further longitudinal scans based on the acquired study data. All participants will have longitudinal clinical, biomarker, and genetic data for correlation analyses to imaging data from the PPMI Clinical study.	Parkinson	Phase 2	Ralentissement de la progression	United States	À vérifier
[18F]PI-2620The study aims to evaluate the burden of tau pathology in people with Sporadic and LRRK2 PD via in vivo imaging using the tau tracer, \[18F\]PI-2620, and a high resolution PET camera, NeuroEXPLORER.	Parkinson	Phase 2	À vérifier	United States	À vérifier
Early Longitudinal Imaging in Parkinson's Progression Markers Initiative Using [¹⁸F] AV-133 and DaTscan™Directly examine whether early (6-month) imaging with DaTscan and \[¹⁸F\] AV-133 will provide an early signal of disease progression in recently diagnosed untreated PD patients.	Parkinson	À vérifier	Ralentissement de la progression	United States	À vérifier
Parkinson Progression Marker Initiative Online (PPMI Online)Parkinson Progression Marker Initiative Online (PPMI Online) is an observational study collecting participant reported information from people with and without Parkinson's disease (PD), for the goal of better understanding risk and predictive factors for PD. PPMI Online is part of the broader Parkinson Progression Marker Initiative aimed at identifying markers of disease progression for use in clinical trials of therapies to reduce progression of PD disability.	Parkinson	À vérifier	Ralentissement de la progression	United States	À vérifier
Early Longitudinal Imaging in Parkinson's Progression Markers Initiative Using [¹⁸F] AV-133 and DaTscan™Directly examine whether early (6-month) imaging with DaTscan and \[¹⁸F\] AV-133 will provide an early signal of disease progression in recently diagnosed untreated PD patients.	Parkinson	À vérifier	Ralentissement de la progression	United States	À vérifier
[18F]PI-2620The study aims to evaluate the burden of tau pathology in people with Sporadic and LRRK2 PD via in vivo imaging using the tau tracer, \[18F\]PI-2620, and a high resolution PET camera, NeuroEXPLORER.	Parkinson	Phase 2	À vérifier	United States	À vérifier
[18F] AV-133 PET ImagingThis study is a single-center, longitudinal study and will be conducted at the Institute for Neurodegenerative (INDD) Site in New Haven, CT. This study aims to recruit participants from the ongoing Parkinson's Progression Markers Initiative AV-133 Prodromal Imaging sub study \[PPMI 015\] to obtain a second comparison imaging scan. In addition to being imaged with the standard Positron Emission Tomography (PET) camera after the \[18F\]AV133 injection in the PPMI 015 sub study, participants agreeing to a second scan will be imaged with the NeuroEXPLORER (NX) PET camera per this protocol. This study will enroll approximately 25 participants at the INDD site. The dual PET scans will be completed at baseline, 1-and 2- years follow up. Participants may be asked to undergo further longitudinal scans based on the acquired study data. All participants will have longitudinal clinical, biomarker, and genetic data for correlation analyses to imaging data from the PPMI Clinical study.	Parkinson	Phase 2	Ralentissement de la progression	United States	À vérifier
Parkinson Progression Marker Initiative Online (PPMI Online)Parkinson Progression Marker Initiative Online (PPMI Online) is an observational study collecting participant reported information from people with and without Parkinson's disease (PD), for the goal of better understanding risk and predictive factors for PD. PPMI Online is part of the broader Parkinson Progression Marker Initiative aimed at identifying markers of disease progression for use in clinical trials of therapies to reduce progression of PD disability.	Parkinson	À vérifier	Ralentissement de la progression	United States	À vérifier

Essais cliniques

4

Molécule	Indication / population	Phase	NCT	Titre	Statut
Parkinson Progression Marker Initiative Online (PPMI Online)	Parkinson	À vérifier	NCT05065060	Parkinson Progression Marker Initiative Online (PPMI Online)	RECRUITING
[18F] AV-133 PET Imaging	Parkinson	Phase 2	NCT07809438	A Comparative Performance Study Between High and Standard Resolution Positron Emission Tomography Camera Using [18F] AV-133 in Prodromal Parkinson's Disease	RECRUITING
[18F]PI-2620	Parkinson	Phase 2	NCT07020026	Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease	RECRUITING
Early Longitudinal Imaging in Parkinson's Progression Markers Initiative Using [¹⁸F] AV-133 and DaTscan™	Parkinson	À vérifier	NCT04507139	Early Longitudinal Imaging in Parkinson's Progression Markers Initiative Using [¹⁸F] AV-133 and DaTscan™	ACTIVE_NOT_RECRUITING

Publications

3

Molécule	Indication / population	Titre	Journal	Date
[18F]PI-2620		Developing a novel reference region for [F]PI-2620-PET imaging to facilitate the assessment of 4-repeat tauopathies.	European journal of nuclear medicine and molecular imaging
[18F]PI-2620		Association of functional brain alterations with β-amyloid, tau, and cognitive decline in Alzheimer's disease.	Alzheimer's research & therapy
[18F]PI-2620		Stage-dependent tau-PET signatures in Huntington's disease revealed by [¹⁸F]PI-2620.	European journal of nuclear medicine and molecular imaging